Literature DB >> 12557140

Liver transplantation improves hepatic myelopathy: evidence by three cases.

Karin Weissenborn1, Uwe J F Tietge, Martin Bokemeyer, Bahram Mohammadi, Ulriue Bode, Michael P Manns, Martin Caselitz.   

Abstract

BACKGROUND & AIMS: Hepatic myelopathy is a rare complication of chronic liver disease, causing progressive spastic paraparesis. Today, no therapy of this disorder has been established. Commonly used therapeutic strategies for hepatic encephalopathy aiming at the reduction of plasma ammonia levels such as protein restriction, oral neomycin, lactulose, or ornithine aspartate fail to improve the symptoms of hepatic myelopathy. The aim of this study was to find out whether orthotopic liver transplantation (OLT) may improve hepatic myelopathy.
METHODS: Follow-up examinations of 3 patients with severe hepatic myelopathy before and after OLT.
RESULTS: In all 3 patients, the neurologic status improved significantly after liver transplantation. The grade of improvement was related to the time interval between onset of the first symptoms of hepatic myelopathy and liver transplantation.
CONCLUSIONS: Early recognition of hepatic myelopathy is important because timely liver transplantation as an established therapy for end-stage liver disease offers the chance of complete recovery from hepatic paraparesis.

Entities:  

Mesh:

Year:  2003        PMID: 12557140     DOI: 10.1053/gast.2003.50062

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  19 in total

Review 1.  Acquired hepatocerebral degeneration.

Authors:  Joseph Ferrara; Joseph Jankovic
Journal:  J Neurol       Date:  2009-02-17       Impact factor: 4.849

2.  Letter to the editor concerning "Hepatic myelopathy with spastic paraparesis: report of two cases and review of the literature" by S. Ben Amor et al. (Eur Spine J. 2013, Jun 1).

Authors:  Raffaele Nardone; Stefan Golaszewski; Yvonne Höller; Francesco Brigo; Eugen Trinka
Journal:  Eur Spine J       Date:  2013-08-21       Impact factor: 3.134

3.  Biexponential analysis of diffusion-tensor imaging of the brain in patients with cirrhosis before and after liver transplantation.

Authors:  L Chavarria; J Alonso; R García-Martínez; F X Aymerich; E Huerga; C Jacas; V Vargas; J Cordoba; A Rovira
Journal:  AJNR Am J Neuroradiol       Date:  2011-06-23       Impact factor: 3.825

Review 4.  Challenges in diagnosing hepatic encephalopathy.

Authors:  K Weissenborn
Journal:  Neurochem Res       Date:  2014-08-21       Impact factor: 3.996

5.  Brain magnetic resonance spectroscopy in episodic hepatic encephalopathy.

Authors:  Laia Chavarria; Juli Alonso; Rita García-Martínez; Macarena Simón-Talero; Meritxell Ventura-Cots; Clara Ramírez; Maria Torrens; Víctor Vargas; Alex Rovira; Juan Córdoba
Journal:  J Cereb Blood Flow Metab       Date:  2012-11-21       Impact factor: 6.200

6.  Hepatic myelopathy: an unusual neurological complication of chronic liver disease presenting as quadriparesis.

Authors:  Prakash Kori; Ritesh Sahu; Anupam Jaiswal; Rakesh Shukla
Journal:  BMJ Case Rep       Date:  2013-06-07

7.  Management of surgical splenorenal shunt-related hepatic myelopathy with endovascular interventional techniques.

Authors:  Mao-Qiang Wang; Feng-Yong Liu; Feng Duan
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

Review 8.  Encephalopathy and liver transplantation.

Authors:  Laia Chavarria; Juan Cordoba
Journal:  Metab Brain Dis       Date:  2012-11-16       Impact factor: 3.584

9.  Transjugular intrahepatic portosystemic shunt combined with esophagogastric variceal embolization in the treatment of a large gastrorenal shunt.

Authors:  Qin Jiang; Ming-Quan Wang; Guo-Bing Zhang; Qiong Wu; Jian-Ming Xu; De-Run Kong
Journal:  World J Hepatol       Date:  2016-07-18

Review 10.  Hepatic myelopathy with spastic paraparesis: report of two cases and review of the literature.

Authors:  Sana Ben Amor; Mohamed Zakaria Saied; Mohamed Salah Harzallah; Sofiene Benammou
Journal:  Eur Spine J       Date:  2013-06-01       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.